ArticleEndocrine-related cancer2025
FT3 and FT3/FT4 ratio are decreased and not compensated by levothyroxine treatment in TKI-treated thyroid cancer patients.
Article in Endocrine-related cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between FT4/FT3 Ratio and Short-Term Treatment Response in Differentiated Thyroid Cancer Patients.International journal of endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tyrosine kinase inhibitors (TKIs) can alter thyroid hormone levels in multiple cancer contexts. The aim of this study was to analyse the efficacy of levothyroxine (LT4) treatment to normalise thyroid hormone levels in thyroid cancer patients with increased thyroid-stimulating hormone (TSH) after TKI initiation. Forty-five consecutive patients were enrolled. One month after TKI initiation, TSH increased from 0.21 (IQR: 0.07-0.8) to 1.09 mIU/L (IQR: 0.16-4.1) (P < 0.0001), and the FT3/FT4 ratio decreased from 2.1 (IQR: 1.86-2.66) to 1.92 (IQR 1.69-2.3) (P < 0.001) compared to baseline. During the first year of TKI treatment, in 23 patients (51%), TSH increased >4 mIU/L with a concomitant decrease in both FT3 and FT4. An increase in the LT4 daily dose of 0.62 ± 0.44 μg/kg normalised TSH to baseline levels in all patients, but in 11 patients FT3 remained lower compared to baseline, i.e. 2.53 (IQR: 2.4-2.75) versus 3.5 pg/mL (IQR: 3.18-3.84), respectively (P = 0.001). Following this observation, in three consecutive patients with increased TSH and reduced FT3 during TKI treatment, we changed the LT4 monotherapy into an LT4 + LT3 combination at a ratio of 11:1. Two months later, serum TSH, FT3 and FT4 were all similar to baseline (P > 0.05 in all determinations). In conclusion, TKI-related increase in TSH was associated with decreased FT3 and FT3/FT4 ratio. This was not compensated by an increase in LT4 in half of the cases. The clinical impact of compensating for the low T3 levels in these patients should be addressed in prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.